The role of multiparametric ultrasound in the detection of clinically significant prostate cancer

被引:3
|
作者
Jung, Nathan [1 ]
DiNatale, Renzo G. [1 ]
Frankel, Jason [2 ]
Koenig, Hannah [1 ]
Ho, On [1 ]
Flores, John Paul [3 ]
Porter, Christopher [1 ]
机构
[1] Virginia Mason Med Ctr, Dept Surg, Urol & Renal Transplantat Serv, 1100 Ninth Ave, Seattle, WA 98101 USA
[2] SLU Care Urol, Urol, 6400 Clayton Rd, Clayton, MO 63177 USA
[3] Virginia Mason Med Ctr, Dept Med, Hematol & Oncol Serv, 1100 Ninth Ave, Seattle, WA 98101 USA
关键词
Imaging-guided biopsy; Multiparametric MRI; Prostate cancer; Sensitivity and specificity; Ultrasonography; SHEAR-WAVE ELASTOGRAPHY; TRANSRECTAL ULTRASOUND; TARGETED BIOPSY; LESIONS; IMPACT;
D O I
10.1007/s00345-022-04122-z
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose Transrectal ultrasound (US) imaging is paramount to the successful completion of prostate biopsies. Certain US features have been associated with prostate cancer (PCa), but their utility remains controversial. We explored the role of multiparametric US (mpUS) in the detection of clinically significant PCa. Methods We performed a retrospective cohort study to contrast the findings of prostate MRI and mpUS. Patients who underwent MRI, US and biopsy between 2015 and 2021 were included. Biopsies were performed using a systematic approach (12 cores), as well as with MRI (4 cores/lesion) and US (1 core/lesion) targeting. The US features analyzed consisted of: calcifications, hypoechoic lesions and power or color Doppler positivity. Gleason 3 + 4 or higher was used as to define true positives. Measures of diagnostic accuracy were calculated for the different imaging modalities. Results The final cohort included 74 patients, of which 24 (32.4%) had clinically significant PCa. The concordance between MRI and US was 63.5%. Seven individuals with discordant results had clinically significant PCa. MRI alone was more sensitive (87.5% vs 75%) but less specific (28% vs 32%) than US alone. An all-inclusive approach considering any suspicious US or MRI finding had a sensitivity of 95.8%. A more restrictive approach, targeting lesions noted in both US and MRI, yielded the highest specificity (50.0%) and accuracy (55.4%). Conclusion Biopsy targeting based on US findings can provide additional diagnostic information that may increase sensitivity or specificity. Additional research into this topic could open the door to a more personalized approach to prostate biopsy.
引用
收藏
页码:663 / 671
页数:9
相关论文
共 50 条
  • [21] Investigating the equivalent performance of biparametric compared to multiparametric MRI in detection of clinically significant prostate cancer
    Baojun Wang
    Jie Gao
    Qing Zhang
    Chengwei Zhang
    Guangxiang Liu
    Wang Wei
    Haifeng Huang
    Yao Fu
    Danyan Li
    Bing Zhang
    Hongqian Guo
    Abdominal Radiology, 2020, 45 : 547 - 555
  • [22] Investigating the equivalent performance of biparametric compared to multiparametric MRI in detection of clinically significant prostate cancer
    Wang, Baojun
    Gao, Jie
    Zhang, Qing
    Zhang, Chengwei
    Liu, Guangxiang
    Wei, Wang
    Huang, Haifeng
    Fu, Yao
    Li, Danyan
    Zhang, Bing
    Guo, Hongqian
    ABDOMINAL RADIOLOGY, 2020, 45 (02) : 547 - 555
  • [23] Multiparametric magnetic resonance imaging-targeted biopsies in the detection of clinically significant prostate cancer
    Charalampos, Fragkoulis
    INDIAN JOURNAL OF UROLOGY, 2020, 36 (03) : 229 - 230
  • [24] Biparametric versus multiparametric MRI for the detection of clinically significant prostate cancer in a diverse, multiethnic population
    Abramson, Max
    DeMasi, Matthew
    Zhu, Denzel
    Hines, Laena
    Lin, Wilson
    Kanmaniraja, Devaraju
    Chernyak, Victoria
    Agalliu, Ilir
    Watts, Kara L.
    ABDOMINAL RADIOLOGY, 2024, 49 (07) : 2491 - 2498
  • [25] Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR
    Metser, Ur
    Ortega, Claudia
    Perlis, Nathan
    Lechtman, Eli
    Berlin, Alejandro
    Anconina, Reut
    Eshet, Yael
    Chan, Rosanna
    Veit-Haibach, Patrick
    van der Kwast, Theodorus H.
    Liu, Amy
    Ghai, Sangeet
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (11) : 3702 - 3711
  • [26] The CADMUS trial: A paired cohort, blinded study comparing multiparametric ultrasound targeted biopsies with multiparametric MRI targeted biopsies in the detection of clinically significant prostate cancer
    Grey, A. D. R.
    Scott, R.
    Shah, B.
    Acher, P.
    Liyanage, S.
    Pavlou, M.
    Omar, R.
    Chinegwundoh, F.
    Patki, P.
    Shah, T. T.
    Hamid, S.
    Ghei, M.
    Brew-Graves, C.
    Arumainayagam, N.
    Chapman, A.
    Mcleavy, L.
    Alsaadi, Z.
    Karatziotou, A.
    Collins, T.
    Eldred-Evans, D.
    Freeman, A.
    Winkler, M.
    Emberton, M.
    Ahmed, H. U.
    EUROPEAN UROLOGY, 2021, 79 : S1301 - S1302
  • [27] Multiparametric Magnetic Resonance Imaging in Evaluation of Clinically Significant Prostate Cancer
    Ingole, Sarang M.
    Mehta, Rajeev U.
    Kazi, Zubair N.
    Bhuyar, Rutuja, V
    INDIAN JOURNAL OF RADIOLOGY AND IMAGING, 2021, 31 (01): : 65 - 77
  • [28] The predictability of multiparametric prostate MRI for clinically significant cancer - a prospective study
    Varol, C.
    Kitzing, Y.
    Raz, O.
    BJU INTERNATIONAL, 2014, 113 : 44 - 44
  • [29] Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling
    Jean-Paul Noujeim
    Yassir Belahsen
    Yolene Lefebvre
    Marc Lemort
    Maxime Deforche
    Nicolas Sirtaine
    Robin Martin
    Thierry Roumeguère
    Alexandre Peltier
    Romain Diamand
    Prostate Cancer and Prostatic Diseases, 2023, 26 : 575 - 580
  • [30] Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling
    Noujeim, Jean-Paul
    Belahsen, Yassir
    Lefebvre, Yolene
    Lemort, Marc
    Deforche, Maxime
    Sirtaine, Nicolas
    Martin, Robin
    Roumeguere, Thierry
    Peltier, Alexandre
    Diamand, Romain
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (03) : 575 - 580